Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2006-03-03
2008-09-02
Carlson, Karen Cochrane (Department: 1656)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S002600, C514S004300, C514S012200, C514S866000, C530S300000, C530S324000
Reexamination Certificate
active
07419952
ABSTRACT:
Methods for treating conditions or disorders which can be alleviated by reducing food intake are disclosed which comprise administration of an effective amount of an exendin or an exendin agonist, alone or in conjunction with other compounds or compositions that affect satiety. The methods are useful for treating conditions or disorders, including obesity, Type II diabetes, eating disorders, and insulin-resistance syndrome. The methods are also useful for lowering the plasma glucose level, lowering the plasma lipid level, reducing the cardiac risk, reducing the appetite, and reducing the weight of subjects. Pharmaceutical compositions for use in the methods of the invention are also disclosed.
REFERENCES:
patent: 5118666 (1992-06-01), Habener
patent: 5120712 (1992-06-01), Habener
patent: 5424286 (1995-06-01), Eng
patent: 5512549 (1996-04-01), Chen
patent: 5545618 (1996-08-01), Buckley
patent: 5574008 (1996-11-01), Johnson
patent: 5677279 (1997-10-01), Young
patent: 5686511 (1997-11-01), Bobo
patent: 5705483 (1998-01-01), Galloway et al.
patent: 5756461 (1998-05-01), Stephens
patent: 5846937 (1998-12-01), Drucker
patent: 6191102 (2001-02-01), DiMarchi et al.
patent: 6506724 (2003-01-01), Hiles et al.
patent: 723694 (1998-01-01), None
patent: WO 90/11296 (1990-04-01), None
patent: WO 91/11457 (1991-08-01), None
patent: WO 93/18786 (1993-09-01), None
patent: WO 93/25579 (1993-12-01), None
patent: WO 96/401096 (1996-12-01), None
patent: WO 97/46584 (1997-12-01), None
patent: WO 98/19698 (1998-05-01), None
patent: WO 98/30231 (1998-07-01), None
patent: WO 98/05351 (1998-12-01), None
patent: WO 99/07404 (1999-02-01), None
Wikipedia (2007, updated) Gestational diabetes, http://en.wikipedia.org/wiki/Gestational—diabetes, p. 1.
Adelhorst, K., et al.,“Structure-Activity Studies of Glucagon-like Peptide-1 (GLP-1),” J. Bio Chem 269(9):6275-8 (1994).
Bartlett, et al., “Inhibition of Chrymotrypsin by Phisphonate and Phosphonamidate Peptide Analogs,” Bioorg.Chem. 14:356-377 (1986).
Bhavsar, “Inhibition of Gastric Emptying and of Food Intake Appear to be Independently Controlled in Rodents,” Soc. Neurosci. Abst. 21:460 (188.8)(1995).
D'Alessio et al., “Elimination of the Action of Glucagon-like Peptide-1 Causes an Impairment of Glucose Tolerance After Nutrient Ingestion by Healthy Baboons,” J. Clin. Invest.
Eissele et al. “Rat Gastric Somatostatin and Gastrin Release: Interactions of Exendin-4 and Truncated Glucagon-like Peptide-1 (GLP-1) Amide,” Life Sci., 55:629-34, (1994).
Eng et al. “Isolation and Characterization of Exendin-4, an Exendin-3 Analogue, from Heloderma suspectum Venom”, J. Biol. Chem., 267:7402-05, (1992).
Eng et al. “Purification and Structure of Exendin-3, a New Pancreatic Secretagogue Isolated from Heloderma horridum Venom,” J. Biol. Chem., 265:20259-62, (1990).
Fehmann et al., “Stable Expression of the Rat GLP-1 Receptor in CHO Cells: Activation and Binding Characteristics Utilizing CLP-1 (7-36)-Amide, Oxyntomodulin, Exendin-4, and Exending (9-39),” Peptides 15(3): 453-6, (1994).
Ferguson et al. “Cell-Surface Anchoring of Proteins via Glycosylphosphatidylinositol Structures”, Annu. Rev. Biochem. 57:285-320.
Goke, et al., “Exendin-4 is a High Potency Agonist and Truncated Exendin-(9-39)-amide an Antagonist at the Glucagon-like Peptide 1-(7-36)-amide Receptor of Insulin-screening β-Cells”, J. Biol. Chem., 268:19650-55, (1993).
Goldstone, et al., “Leptin Interacts with GLucagon-like Peptide-1 Neutron to Reduce Food Intake and Body Weight in Rodents,” FEBS Letters, 415:134-138, (1997).
Halaas, J. L., et al., “Weight-Reducing Effects of the Plasma Protein Encoded by the Obese Gene,” Science 269:543-546, (1995).
Kodama, J., et al. “Effect of Captopril on Gluclose Concentration Possible Role of Augmented Postprandial Forearm Blood Flow,” Diabetes Care 13(11):1109-1111, (1990).
Kolligs, et al. “Reduction of the Incretin Effect in Rats by the Glucagon-like Peptide-1 Receptor Antagonist Exendin (9-39) Amide,” Diabetes 44:16-19, (1995).
Leibel, R.L., et al., Changes in Energy Expenditures Resulting from Altered Body Weight, New England Journal of Medicine, 332 (10):621-628, (1995).
Lithell, et al., “Insulin Sensitivity in Newly Detected Hypertensive Patients: Influence of Captopril and Other Antihypertensive Agents on Insulin Sensitivity and Related Biological Parameters,” J. Cardovasc. Pharmacol. 15 (Supp 5): S46-S52, (1990).
Malhotra, et al., “Exendin-4, A New Peptide fromn Heloderma suspectum Venom, Potentiates Cholecystrokimin-induced Amylase Release from Rat Pancreatic Acini”, Regulatory Peptide, 41: 149-56, (1992).
Montrose-Rafizadeh, et al., “Structure-function Analysis of Exendin-4/GLP-1 Analogs”, Diabetes, 45 (Suppl. 2): 152A, (1996).
Navarro, M. et al., “Colocalization of Glucagon-Like Peptide-1 (GLP-1) Receptors, Glucose Transporter GLUT-2, and Glucokinase mRNAs in Rat Hypothalamic Cells: Evidence for a Role of GLP-1 Receptor Agonists as an Inhibitory Signal for Food and Water Intake,” Journal of.
O'Halloran et al., “Glucagon-like Peptide-1 (7-36)-NH2: a Physiological Inhibitor of Gastric Acid Secretion in Man,” J. Endocrinol 126 (1): 169-73, (1990).
Orskov, et al. “Biological Effects and Metabolic Rates of Glucagonlike Peptide-1 7-36 Amide and Glucagonlike Peptide-1 7-37 in Healthy Subjects are Indistinguishable,” Diabetes, 42: 658-61, (1993).
Pelleymounter, et al., “Effects of the Obese Gene Product on Body Weight Regulation in OB/OB Mice,” Science 269: 540-43, (1995).
Raufman, et al. “Truncated Glucagon-like Peptide-1 Interacts with Exendin Receptors in Dispersed Acini from Pig Pancreas,” J. Biol. Chem. 267: 21432-37, (1992).
Raufman, et al. “Exendin-3, a Novel Peptide from Heloderma horridum Venom, Interacts with Vasoactive Intestinal Peptide Receptros and a Newly Described Receptor on Dispersed Acini from Guinea Pig Pancreas,” J. Biol. Chem., 266: 2897-902, (1991).
Schepp, et al., “Exendin-4 and Exendin-(9-39) NH2: Agonist and Antagonist respectively, at the Rat Parietal Cell Receptor for Glucagon-like Peptide-1-(7-36) NH2,” Eur. J. Pharm, 269: 183-91, (1994).
Schjoldager, et al. “GLP-1 (Glucagon-like Peptide 1) and Truncated GLP-1, Fragments of Human Proglucagon, Inhibit Gastric Acid Secretion in Humans,” Dig. Dis Sci 34 (5): 703-8, (1989).
Singh, et al. “Use of 1-[Y] Exendin-4 to Characterize Exendin Receptors on Dispersed Pancreatic Acini and Gastric Chief from Guinea Pig,” Regul. Pept. 53: 47-59, (1994).
Thorens, “Expression Cloning of the Pancreatic Cell Receptor for the Glucoincretin Hormone Glucagon-like Peptide 1,” Proc. Natl. Acad. Sci. USA 89: 8641-45, (1992).
Thorens, et al. “Cloning and Functional Expression of the Human Islet GLP-1 Receptor,” Diabetes 42 (11): 1678-82, (1993).
Turton, et al., “A Role of Glucagon-like Peptide-1 in the Central Regulation in Feeding,” Nature 379:69-72, (1996).
Veale, P.R., et al., “The Presence of Islet Amyloid Polypeptide/Calcitonin Gen-related Peptide/Salmon Calcitronin Binding Sites in the Rat Nucleaus Accumbens,” European Journal of Pharmacology 262:133-141, (1994).
Wang, et al. “Glucagon-like Peptide-1 Is a Physiological Incretin in Rat,” J. Clin. Invest., 95:417-21, (1995).
Watson, N.,, et al., “Effects of Captopril on Glucose Tolerance in Elderly Patients with Congestive Cardiac Failure,” Current Medical Research and Opinion 12(6): 374-78, (1991).
Wettergren, et al. “Truncated GLP-1 (Proglucagon 78-107-Amide) Inhibits Gastric and Pancreatic Functions in Man,” Dig Dis Sci. 38 (4): 665-73, (1993).
Willms, et al. “Gastric Emptying, Glucose Responses, and Insulin Secretion After a Liquid Test Mel: Effects pf Exogenous Glucagon-Like Peptide-1 (GLP-
Beeley Nigel Robert Arnold
Bhavsar Sunil
Prickett Kathryn S.
Young Andrew A.
Amylin Pharmaceuticals Inc.
Carlson Karen Cochrane
Liu Samuel W.
LandOfFree
Use of exendins and agonists thereof to treat diabetes does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of exendins and agonists thereof to treat diabetes, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of exendins and agonists thereof to treat diabetes will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3984059